Fig. 4

In vivo treatment with Ch’ase sensitizes blasts to VxL, rendering higher CR rates and higher EFS in preclinical PDX models of MLLr-B-ALL. a Complete experimental design of the preclinical PDX models detailing in vivo treatments with VxL and NG2 antagonists. After 2 complete cycles of VxL chemotherapy, MRD/CR was evaluated and relapse was followed-up for up to 30 days. b Monitoring of the levels of leukemic engraftment in PB and BM for the indicated treatments. PB engraftment was analyzed weekly. BM leukemic engraftment was analyzed using BM aspirates at the end of VxL ± Ch’ase treatment (day 15) and at the end of the follow-up period (day 50). Each line represents the same mouse before and after treatment. c Levels of leukemia engraftment in BM at treatment initiation (day 0) for VxL or VxL + Ch’ase mice cohorts. d BM levels of MRD at the end of two cycles of VxL ± Ch’ase (day 15). Each dot represents a single mouse. A mouse is considered in CR when the % of blasts in BM <1% (blue horizontal dotted line). The light blue bars represent the proportion of mice in CR (right Y-axis) for VxL and VxL + Ch’ase (n = 18 mice/group). e Kaplan–Meier survival curves for 45 days EFS (n = 16 mice). f Leukemic burden in BM at sacrifice. *p < 0.05; n.s.: no significant differences